Last reviewed · How we verify
NCT05433961
Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
Phase 1 trial testing MagniXene Hyperpolarized Xenon MRI in COPD in 27 participants. Terminated before completion.
11 September 2025
Quick facts
| Lead sponsor | Xemed LLC |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 27 |
| Start date | 20 October 2023 |
| Primary completion | 11 September 2025 |
| Estimated completion | 11 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MagniXene Hyperpolarized Xenon MRI — full drug profile →
Conditions studied
- COPD — all drugs for COPD →
Sponsor
Xemed LLC — full company profile →
Who can join
Adults 18 to 85, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care. Once inhaled, HP xenon can provide information to imagers regarding functionality across specific regions of the lungs through the assessment of the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the normal spongy tissue structure has been compromised by lung disease. Pre- (baseline) and post-EBV (follow-up) lung function imaging with HPXe will potentially lead to be better understand disease progression and treatment mechanism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05433961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Xemed LLC trials
Trials by the same sponsor.
- NCT04035629 — 129Xe MRI in Pediatric Population With BPD · Phase 1 · withdrawn
- NCT07355231 — Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI · Phase 1, PHASE2 · not yet recruiting
- NCT05816616 — Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation · withdrawn
- NCT05302817 — Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI · Phase 1 · terminated
- NCT04941573 — Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05433961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xemed LLC
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing